Prosecution Insights
Last updated: September 17, 2026

Fulcrum Therapeutics Inc.

4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready

Portfolio Summary

4
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (50%)
0
Medium (0%)
2
Easy (50%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only2 (50%)
Multi-statute (no §101)2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
75% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
25% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SEAMAN, D MARGARET M 1 76.5% +8.0%
HAVLIN, ROBERT H 1 51.4% +28.1%
KENYON, JOHN S 1 80.0% +17.8%
EBBINGHAUS, BRIANA NOEL 1 62.5% +62.7%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18553352 POLYMORPHIC FORMS OF (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINE HAVLIN, ROBERT H 71d overdue
18553317 MACROCYCLIC AZOLOPYRIDINES KENYON, JOHN S —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18553352 POLYMORPHIC FORMS OF (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINE HAVLIN, ROBERT H 71d overdue
18553317 MACROCYCLIC AZOLOPYRIDINES KENYON, JOHN S —
17295782 COMPOSITIONS AND METHODS FOR INCREASING FETAL HEMOGLOBIN AND TREATING SICKLE CELL DISEASE EBBINGHAUS, BRIANA NOEL —

Top Art Units

Art UnitApps
1626 1
1625 1
1632 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18783250 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS SEAMAN, D MARGARET M — §112 Non-Final OA — Pending Jul 24, 2024
18553352 POLYMORPHIC FORMS OF (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINE HAVLIN, ROBERT H 1626 §102§103Other Final Rejection 71d overdue Pending Sep 29, 2023
18553317 MACROCYCLIC AZOLOPYRIDINES KENYON, JOHN S 1625 §103§112 Non-Final OA — Pending Sep 29, 2023
17295782 COMPOSITIONS AND METHODS FOR INCREASING FETAL HEMOGLOBIN AND TREATING SICKLE CELL DISEASE EBBINGHAUS, BRIANA NOEL 1632 §112 Non-Final OA — Pending May 20, 2021

Managing Fulcrum Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month